Posted: August 5, 2022 at 2:03 am
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell) (Nasdaq: LYEL), a clinical?stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today provided business highlights and reported financial results for the second quarter of 2022.
Excerpt from:
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights
Posted: August 5, 2022 at 2:03 am
WALTHAM Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to two new employees with a grant date of August 1, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Continued here:
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted: August 5, 2022 at 2:03 am
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2022 and provided business updates.
See the original post here:
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Posted: August 5, 2022 at 2:03 am
Cash balance of $312.2M expected to fund operations into 2025 Cash balance of $312.2M expected to fund operations into 2025
See the original post here:
Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results
Posted: August 5, 2022 at 2:03 am
- Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation conditionally activated therapeutics, extending cash runway to 2025 -
View original post here:
CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Posted: August 5, 2022 at 2:03 am
The rest is here:
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022
Posted: August 5, 2022 at 2:03 am
Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline results for full pivotal study population expected in the first quarter of 2023
Read the original here:
Day One Reports Second Quarter 2022 Financial Results and Corporate Progress
Posted: August 5, 2022 at 2:03 am
Company expects to report results of preclinical MPS-1 studies in second half of 2022 to inform pipeline strategy Company expects to report results of preclinical MPS-1 studies in second half of 2022 to inform pipeline strategy
Excerpt from:
Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Posted: August 5, 2022 at 2:03 am
BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, reported today second quarter 2022 financial results. The Company will host a business update call and webcast on Tuesday, August 23, 2022 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website.
More:
Cue Biopharma Reports Second Quarter 2022 Financial Results
Posted: August 5, 2022 at 2:03 am
-- Secured $68.9 million in committed financing through a combination of equity and non-dilutive debt financing ---- Cash runway anticipated to extend through 2023 with $43.9 million funded at closing and an additional $25.0 million of availability through April 2023, subject to a minimum revenue target --
Original post:
RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing
